Genentech

TheStreet.com BioTalk: DNDN, DNA

The Street (Free subscription) | 04/10/2008

Adam Feuerstein and Elizabeth Trotta look at news to come: Dendreon's interim data and Roche's bid for Genentech.

Genentech Issues Dear Healthcare Provider Letter Regarding A Reported Case Of PML In A Raptiva Patient

Medical News Today (Free subscription) | 04/10/2008

Genentech, Inc. (NYSE: DNA) announced that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva® (efalizumab) for more than four years for treatment of chronic plaque psoriasis. The company will work with the U.S.

Technical Trade Alerts on Recent Analyst upgrade Notables: DISH, DNA, RT, LEA, IRM, ERES

EmailWire.Com (Free subscription) | 04/10/2008

(EMAILWIRE.COM, October 04, 2008 ) DALLAS, Texas – Beacon Equity Research announces the release of a Trade Alerts covering upgrade Notables: Dish Network Corp. (Nasdaq: DISH), Genentech Inc. (NYSE: DNA), Ruby Tuesday Inc. (NYSE: RT), Lear Corp. (NYSE: LEA), Iron Mountain Inc. (NYSE: IRM) and eResearchTechnology...

• Technical Trade Alerts on Recent Analyst upgrade Notables: DISH, DNA, RT, LEA, IRM, ERES - The Earth Times Online Newspaper
• Technical Trade Alerts on Recent Analyst upgrade Notables: DISH, DNA, RT, LEA, IRM, ERES - The Earth Times Online Newspaper

Genetic tests may pinpoint who should get Avastin

Reuters UK (Free subscription) | 03/10/2008

LONDON (Reuters) - Genetic tests could in future show who will respond best to Genentech and Roche's blockbuster cancer drug Avastin -- a positive development for patients but not necessarily for sales.

Developing GA101, A Humanized Anti-CD20 Monoclonal Antibody With Hematological Malignancies Potential Treatment - Genentech, GlycArt And Roche Collabo

Medical News Today (Free subscription) | 03/10/2008

Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule.

• Genentech, Roche in cancer treatment collaboration - bizjournals
• Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy - Red Orbit
• See the 7 articles on the same subject

Genentech: Raptiva Patient Has Brain Infection

Pharmalot (Free subscription) | 03/10/2008

The biotech is sending a letter to healthcare professionals about the case of a 70-year-old man who was being treated for psoriasis for more than four years with its med, and developed a rare brain infection known as progressive multifocal leukoencephalopathy, or PML. Genentech says there are no other cases of confirmed PML in patients treated [...]

Severe Adverse Event Reported In Raptiva Patient

Medical News Today (Free subscription) | 03/10/2008

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Genentech Inc. has reported a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva (efalizumab) for more than four years of treatment of chronic plaque psoriasis. Genentech markets Raptiva in the United States.

Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy

The Earth Times Online Newspaper (Free subscription) | 03/10/2008

SCHLIEREN/BASEL, Switzerland & SOUTH SAN FRANCISCO, Calif. - Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercializati

• Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy - Business Wire
• Roche Diagnostics Extends License for Universal ProbeLibrary (UPL) Kits from Exiqon A/S - Business Wire

Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient

Red Orbit (Free subscription) | 03/10/2008

PML is a rare, progressive, demyelinating disease of the central nervous system that usually leads to death or severe disability. PML is caused by activation of the John Cunningham, (JC) virus. JC virus resides in latent form in up to 80 percent of healthy adults, typically only causing PML in immunocompromised patients. The factors leading to activation of the latent infection are not fully understood,...

• Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient - Business Wire

Roche: Economic crisis won't stop Genentech bid

Fiercebiotech (Free subscription) | 02/10/2008

Roche is reassuring everyone that despite all the market turmoil that has occurred worldwide in recent weeks, it's still on track to raise the $43.7 billion it's bid to acquire all the outstanding shares of Genentech. And that's a major issue for the investment field, which sees that deal as a sign that the M&A business isn't completely dead --for now. A spokesperson for Roche declined, though, to...

Roche Says Offer Is on Track

Law Blog - WSJ.com (Free subscription) | 02/10/2008

Roche remains confident it can raise the money it needs for its $43.7 billion bid for Genentech.

Roche Says Bid Is on Track

Law Blog - WSJ.com (Free subscription) | 02/10/2008

Roche remains confident it can raise the money it needs for its $43.7 billion bid for full ownership of Genentech, despite turmoil in financial markets.

Europe's biotech is starving

PharmaGossip (Free subscription) | 01/10/2008

Europe's biotech sector is being hit hard by the credit crunch, with small and medium-sized companies being starved of funding from venture capitalists. As a result, Europe's dream to compete with the US biotech sector and create a heavyweight to rival Amgen or Genentech could be over, as increasing numbers of the continent's biotechs are bought out by big pharma. More at Pharmafocus

'Mad Money Lightning Round': Sell Genentech

The Street (Free subscription) | 30/09/2008

Cramer advises home guyers to sell the stock instead of waiting for a higher bid.

Winners & Losers: Wachovia Drops More Than 81%; Apple Shares Plummet; Genentech Slips

World of stocks (Free subscription) | 30/09/2008

TheStreet.com Winners & Losers Financial Winners & Losers: Wachovia Tech Winners & Losers: Apple 9/29/2008 2:34 PM EDT Health Winners & Losers: Genentech 9/29/2008 3:57 PM EDT Cramer: Here's What's in Store 9/29/2008 2:53 PM EDT More News from TheStreet.com ETFs Small Business Investing A-Z Life and Money Moneymaking Strategies Jim Cramer to Reveal 2009 Stock Outlook at Investment Conference Register...